Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Ho, Jennifer E.Yin, Xiaoyan
Levy, Daniel
Vasan, Ramachandran S.
Magnani, Jared W.
Ellinor, Patrick T.
McManus, David D.
Lubitz, Steven A.
Larson, Martin G.
Benjamin, Emelia J.
UMass Chan Affiliations
Meyers Primary Care InstituteDepartment of Medicine, Division of Cardiovascular Medicine
Document Type
Journal ArticlePublication Date
2014-05-01Keywords
AgedAtrial Fibrillation
Biological Markers
Cardiomyopathies
Disease Progression
Echocardiography
Enzyme-Linked Immunosorbent Assay
Female
Fibrosis
Follow-Up Studies
Galectin 3
Heart Atria
Humans
Incidence
Male
Middle Aged
Proportional Hazards Models
Retrospective Studies
Risk Factors
United States
UMCCTS funding
Cardiology
Cardiovascular Diseases
Clinical Epidemiology
Translational Medical Research
Metadata
Show full item recordAbstract
BACKGROUND: Galectin 3 (Gal-3) is a potential mediator of cardiac fibrosis, and Gal-3 concentrations predict incident heart failure. The same mechanisms that lead to cardiac fibrosis in heart failure may influence development of atrial fibrosis and atrial fibrillation (AF). We examined the association of Gal-3 and incident AF in the community. METHODS: Plasma Gal-3 concentrations were measured in 3,306 participants of the Framingham Offspring cohort who attended the sixth examination cycle (1995-1998, mean age 58 years, 54% women). Cox proportional hazards regression models were used to assess the association of baseline Gal-3 concentrations and incident AF. RESULTS: Over a median follow-up period of 10 years, 250 participants developed incident AF. Crude incidence rates of AF by increasing sex-specific Gal-3 quartiles were 3.7%, 5.9%, 9.1%, and 11.5% (log-rank test P < .0001). In age- and sex-adjusted analyses, each 1-SD increase in loge-Gal-3 was associated with a 19% increased hazard of incident AF (hazard ratio 1.19, 95% CI 1.05-1.36, P = .009). This association was not significant after adjustment for traditional clinical AF risk factors (hazard ratio 1.12, 95% CI 0.98-1.28, P = .10). CONCLUSION: Higher circulating Gal-3 concentrations were associated with increased risk of developing AF over the subsequent 10 years in age- and sex-adjusted analyses but not after accounting for other traditional clinical AF risk factors. Our results do not support a role for Gal-3 in AF risk prediction. Further studies are needed to evaluate whether Gal-3 plays a role in the development of AF substrate similar to HF.Source
Ho JE, Yin X, Levy D, Vasan RS, Magnani JW, Ellinor PT, McManus DD, Lubitz SA, Larson MG, Benjamin EJ. Galectin 3 and incident atrial fibrillation in the community. Am Heart J. 2014 May;167(5):729-34.e1. doi: 10.1016/j.ahj.2014.02.009.
DOI
10.1016/j.ahj.2014.02.009Permanent Link to this Item
http://hdl.handle.net/20.500.14038/50343PubMed ID
24766984Related Resources
ae974a485f413a2113503eed53cd6c53
10.1016/j.ahj.2014.02.009